Abstract: In this paper, two criterions of MDS Euclidean self-orthogonal codes are presented. New MDS Euclidean self-dual codes and self-orthogonal codes are constructed via the criterions. In ...

Multiomics integration identified 31 candidate genes that may underlie early decitabine resistance and suggest sensitization strategies. To enable comparable cytotoxicity, optimized conditions were ...

After three quiet years, the MDS returned to Peru and wasted no time reminding everyone why this race holds such a special place in the calendar. Nearly 300 participants from 37 countries lined up for ...

AbbVie remains a Buy despite venetoclax's MDS trial failure, as this setback has minimal impact on current revenue and growth outlook. SKYRIZI and RINVOQ are successfully replacing HUMIRA's lost ...

Exclusive Coverage: Receive ~30 original stories daily, exclusively written for a professional audience, that offer an in-depth look on pressing energy and environmental topics. A Powerful Platform: ...

Incidence of myelodysplastic syndrome in patients treated with PARP inhibitors: A systematic review. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

A MULTICENTRE study, presented at EBMT 2025 Annual Meeting, sheds light on the outcomes of allogeneic hematopoietic cell transplantation (HCT) in patients with MDS/AML (Myelodysplastic Syndromes/Acute ...

1. In patients with treatment-naive high-risk myelodysplastic syndromes (HR MDS), the use of venetoclax (14 days) plus azacitidine was well tolerated. 2. In patients with treatment-naive HR MDS, ...

Background: Current methods of measuring disease progression of neurodegenerative disorders, including Parkinson's disease (PD), largely rely on composite clinical rating scales, which are prone to ...

Younger patients with relapsed MDS may benefit from DLI post-stem cell transplant, improving overall survival rates. DLI is associated with graft-versus-host disease, but its impact on prognosis is ...